| Oracle CRM | 60.0 | 6 | 0 |
| Oracle Fusion Applications | 60.0 | 6 | 0 |
| Oracle Database | 55.2 | 5 | 0 |
| Zenoti | 53.9 | 2 | 1 |
| World Wide Web Consortium | 49.6 | 4 | 0 |
| Extensible HyperText Markup Language | 49.6 | 4 | 0 |
| Spotify | 49.6 | 4 | 0 |
| Atlassian | 49.6 | 4 | 0 |
| Nature Structural & Molecular Biology | 49.6 | 4 | 0 |
| Oracle E-Business Suite | 49.6 | 4 | 0 |
| XML Schema | 42.7 | 3 | 0 |
| XSLT | 42.7 | 3 | 0 |
| JDeveloper | 42.7 | 3 | 0 |
| Jakarta EE | 42.7 | 3 | 0 |
| Nature Methods | 42.7 | 3 | 0 |
| Oracle SQL Developer | 42.7 | 3 | 0 |
| Nature Reviews Genetics | 42.7 | 3 | 0 |
| Psychological Bulletin | 42.7 | 3 | 0 |
| Neuropsychopharmacology | 42.7 | 3 | 0 |
| Cultural Diversity and Ethnic Minority Psychology | 42.7 | 3 | 0 |
| Health Psychology | 42.7 | 3 | 0 |
| Journal of Occupational Health Psychology | 42.7 | 3 | 0 |
| Medicare Advantage | 42.7 | 3 | 0 |
| Psychology of Aesthetics, Creativity, and the Arts | 42.7 | 3 | 0 |
| Eye | 42.7 | 3 | 0 |
| The Pharmacogenomics Journal | 42.7 | 3 | 0 |
| Neuropsychology | 42.7 | 3 | 0 |
| Journal of Latina/o Psychology | 42.7 | 3 | 0 |
| International Journal of Impotence Research | 42.7 | 3 | 0 |
| Mucosal Immunology | 42.7 | 3 | 0 |
| Datalogix | 42.7 | 3 | 0 |
| Npj Quantum Information | 42.7 | 3 | 0 |
| Oracle ERP Cloud | 42.7 | 3 | 0 |
| Oracle Cloud Platform | 42.7 | 3 | 0 |
| Oracle HCM Cloud | 42.7 | 3 | 0 |
| Fitness First | 40.0 | 0 | 3 |
| Nature Reviews Immunology | 33.9 | 2 | 0 |
| Nature Reviews Drug Discovery | 33.9 | 2 | 0 |
| Semantic Web | 33.9 | 2 | 0 |
| Nature | 33.9 | 2 | 0 |
| Nature Reviews Clinical Oncology | 33.9 | 2 | 0 |
| Groupon | 33.9 | 2 | 0 |
| Nature Chemical Biology | 33.9 | 2 | 0 |
| Nature Nanotechnology | 33.9 | 2 | 0 |
| Nature Genetics | 33.9 | 2 | 0 |
| Nature Immunology | 33.9 | 2 | 0 |
| Nature Reviews Microbiology | 33.9 | 2 | 0 |
| Journal of Personality and Social Psychology | 33.9 | 2 | 0 |
| Journal of Consulting and Clinical Psychology | 33.9 | 2 | 0 |
| Nature Geoscience | 33.9 | 2 | 0 |
| Oncogene | 33.9 | 2 | 0 |
| Nature Reviews Molecular Cell Biology | 33.9 | 2 | 0 |
| Nature Cell Biology | 33.9 | 2 | 0 |
| Nature medicine | 33.9 | 2 | 0 |
| Nature Climate Change | 33.9 | 2 | 0 |
| Nature Materials | 33.9 | 2 | 0 |
| Oracle Application Server | 33.9 | 2 | 0 |
| Nature Reviews Endocrinology | 33.9 | 2 | 0 |
| Nature Reviews Nephrology | 33.9 | 2 | 0 |
| Nature Reviews Neurology | 33.9 | 2 | 0 |
| Nature Reviews Rheumatology | 33.9 | 2 | 0 |
| Nature Chemistry | 33.9 | 2 | 0 |
| Prostate Cancer and Prostatic Diseases | 33.9 | 2 | 0 |
| Nature China | 33.9 | 2 | 0 |
| Nature Photonics | 33.9 | 2 | 0 |
| Nature Physics | 33.9 | 2 | 0 |
| Nature Reviews Cardiology | 33.9 | 2 | 0 |
| Siebel Systems | 33.9 | 2 | 0 |
| European Journal of Human Genetics | 33.9 | 2 | 0 |
| Cell Death and Disease | 33.9 | 2 | 0 |
| Heredity | 33.9 | 2 | 0 |
| Scientific Reports | 33.9 | 2 | 0 |
| Blood Cancer Journal | 33.9 | 2 | 0 |
| Vantive | 33.9 | 2 | 0 |
| Cell Death & Differentiation | 33.9 | 2 | 0 |
| American Academy of Facial Plastic and Reconstructive Surgery | 33.9 | 2 | 0 |
| Archives of Scientific Psychology | 33.9 | 2 | 0 |
| Bone Marrow Transplantation | 33.9 | 2 | 0 |
| British Dental Journal | 33.9 | 2 | 0 |
| L Catterton | 33.9 | 2 | 0 |
| Developmental Psychology | 33.9 | 2 | 0 |
| Dreaming | 33.9 | 2 | 0 |
| Emotion | 33.9 | 2 | 0 |
| Group Dynamics: Theory, Research, and Practice | 33.9 | 2 | 0 |
| International Journal of Obesity | 33.9 | 2 | 0 |
| International Journal of Play Therapy | 33.9 | 2 | 0 |
| Java BluePrints | 33.9 | 2 | 0 |
| Journal of Comparative Psychology | 33.9 | 2 | 0 |
| Journal of Educational Psychology | 33.9 | 2 | 0 |
| Journal of Experimental Psychology: General | 33.9 | 2 | 0 |
| Journal of Experimental Psychology: Human Perception and Performance | 33.9 | 2 | 0 |
| Journal of Neuroscience, Psychology, and Economics | 33.9 | 2 | 0 |
| Journal of Theoretical and Philosophical Psychology | 33.9 | 2 | 0 |
| Laboratory Investigation | 33.9 | 2 | 0 |
| Leukemia | 33.9 | 2 | 0 |
| Molecular Psychiatry | 33.9 | 2 | 0 |
| Oracle Property Manager | 33.9 | 2 | 0 |
| Pediatric Research | 33.9 | 2 | 0 |
| Personality Disorders: Theory, Research, and Treatment | 33.9 | 2 | 0 |
| Professional Psychology: Research and Practice | 33.9 | 2 | 0 |
| Psychoanalytic Psychology | 33.9 | 2 | 0 |
| Psychological Assessment | 33.9 | 2 | 0 |
| Psychological Services | 33.9 | 2 | 0 |
| Psychological Review | 33.9 | 2 | 0 |
| Psychological Trauma: Theory, Research, Practice, and Policy | 33.9 | 2 | 0 |
| Psychology and Aging | 33.9 | 2 | 0 |
| Psychology of Addictive Behaviors | 33.9 | 2 | 0 |
| Psychology of Popular Media Culture | 33.9 | 2 | 0 |
| Psychology of Religion and Spirituality | 33.9 | 2 | 0 |
| Psychology of Violence | 33.9 | 2 | 0 |
| Psychotherapy | 33.9 | 2 | 0 |
| Rehabilitation Psychology | 33.9 | 2 | 0 |
| School Psychology Quarterly | 33.9 | 2 | 0 |
| Sport, Exercise, and Performance Psychology | 33.9 | 2 | 0 |
| Training and Education in Professional Psychology | 33.9 | 2 | 0 |
| Immunology & Cell Biology | 33.9 | 2 | 0 |
| Journal of Cerebral Blood Flow & Metabolism | 33.9 | 2 | 0 |
| Couple and Family Psychology | 33.9 | 2 | 0 |
| Journal of Psychotherapy Integration | 33.9 | 2 | 0 |
| International Perspectives in Psychology | 33.9 | 2 | 0 |
| International Journal of Stress Management | 33.9 | 2 | 0 |
| Clinical Practice in Pediatric Psychology | 33.9 | 2 | 0 |
| Translational Psychiatry | 33.9 | 2 | 0 |
| Nature Clinical Practice Cardiovascular Medicine | 33.9 | 2 | 0 |
| American Journal of Orthopsychiatry | 33.9 | 2 | 0 |
| European Journal of Clinical Nutrition | 33.9 | 2 | 0 |
| Cancer Gene Therapy | 33.9 | 2 | 0 |
| Gene Therapy | 33.9 | 2 | 0 |
| Genetics in Medicine | 33.9 | 2 | 0 |
| PsycCritiques | 33.9 | 2 | 0 |
| HealthGrades | 33.9 | 2 | 0 |
| Performance Analyzer | 33.9 | 2 | 0 |
| Psychology of Sexual Orientation and Gender Diversity | 33.9 | 2 | 0 |
| Spirituality in Clinical Practice | 33.9 | 2 | 0 |
| Evolutionary Behavioral Sciences | 33.9 | 2 | 0 |
| Journal of Experimental Psychology: Animal Learning and Cognition | 33.9 | 2 | 0 |
| Journal of Rural Mental Health | 33.9 | 2 | 0 |
| Oracle BlueKai Data Management Platform | 33.9 | 2 | 0 |
| American Psychological Foundation | 33.9 | 2 | 0 |
| Nature Reviews Disease Primers | 33.9 | 2 | 0 |
| Nature Energy | 33.9 | 2 | 0 |
| Clinical and translational gastroenterology | 33.9 | 2 | 0 |
| Nutrition & Diabetes | 33.9 | 2 | 0 |
| Oncogenesis | 33.9 | 2 | 0 |
| NPJ primary care respiratory medicine | 33.9 | 2 | 0 |
| Psychology of consciousness (Washington, D.C.) | 33.9 | 2 | 0 |
| Decision (Washington, D.C.) | 33.9 | 2 | 0 |
| Nature Plants | 33.9 | 2 | 0 |
| Horticulture research | 33.9 | 2 | 0 |
| NPJ Breast Cancer | 33.9 | 2 | 0 |
| NPJ Parkinson’s disease | 33.9 | 2 | 0 |
| NPJ aging and mechanisms of disease | 33.9 | 2 | 0 |
| Light: Science & Applications | 33.9 | 2 | 0 |
| NPJ Vaccines | 33.9 | 2 | 0 |
| Nature Ecology & Evolution | 33.9 | 2 | 0 |
| Nature Human Behaviour | 33.9 | 2 | 0 |
| Oracle Cloud | 33.9 | 2 | 0 |
| Nature Astronomy | 33.9 | 2 | 0 |
| Nature Electronics | 33.9 | 2 | 0 |
| npj Computational Materials | 33.9 | 2 | 0 |
| npj Microgravity | 33.9 | 2 | 0 |
| Qualitative Psychology | 33.9 | 2 | 0 |
| Scholarship of teaching and learning in psychology | 33.9 | 2 | 0 |
| OntoLex | 33.9 | 2 | 0 |
| Q96602914 | 33.9 | 2 | 0 |
| Journal of Threat Assessment and Management | 33.9 | 2 | 0 |
| Spotify Wrapped | 33.9 | 2 | 0 |
| W3C Document License | 33.9 | 2 | 0 |
| WebMD Magazine | 33.9 | 2 | 0 |
| The Internicola Law Firm, PC | 33.9 | 2 | 0 |
| American Academy of Facial Plastic and Reconstructive Surgery | 33.9 | 2 | 0 |
| Georgia Outdoor Services | 33.9 | 2 | 0 |
| dermal fillers | 31.7 | 0 | 2 |
| GoodLeap | 31.7 | 0 | 2 |
| Patient factors influencing dermal filler complications: prevention, assessment, and treatment | 31.7 | 0 | 2 |
| “Home of Younger Skin” (HOYS) program: Defining the change in apparent skin age after facial treatment with botulinum toxin and dermal fillers | 31.7 | 0 | 2 |
| Evaluation of a new hyaluronic acid dermal filler for volume restoration | 31.7 | 0 | 2 |
| Comparison of a series of superficial chemical peels with a single midlevel chemical peel for the correction of facial actinic damage | 31.7 | 0 | 2 |
| The Efficacy and Safety of Lidocaine-Containing Hyaluronic Acid Dermal Filler for Treatment of Nasolabial Folds: A Multicenter, Randomized Clinical Study | 31.7 | 0 | 2 |
| Use of AccuVein™ for preventing complications from accidental venipuncture when administering dermal filler injections | 31.7 | 0 | 2 |
| Combination chemical peels are more effective than single chemical peel in treatment of mild-to-moderate acne vulgaris: A split face comparative clinical trial | 31.7 | 0 | 2 |
| Spacest.com | 31.7 | 0 | 2 |
| Solas Health & Wellness | 31.7 | 0 | 2 |
| Greenwich Medical Spa | 31.7 | 0 | 2 |
| Java | 21.4 | 1 | 0 |
| Q2078 | 21.4 | 1 | 0 |
| Document Object Model | 21.4 | 1 | 0 |
| XML | 21.4 | 1 | 0 |
| HTML | 21.4 | 1 | 0 |
| Solaris | 21.4 | 1 | 0 |
| XPath | 21.4 | 1 | 0 |
| Oracle Corporation | 21.4 | 1 | 0 |
| AOL | 21.4 | 1 | 0 |
| XSL | 21.4 | 1 | 0 |
| XSL Formatting Objects | 21.4 | 1 | 0 |
| Scientific American | 21.4 | 1 | 0 |
| PL/SQL | 21.4 | 1 | 0 |
| N-Triples | 21.4 | 1 | 0 |
| Oracle Linux | 21.4 | 1 | 0 |
| Cascading Style Sheets | 21.4 | 1 | 0 |
| SPARQL | 21.4 | 1 | 0 |
| AOL Instant Messenger | 21.4 | 1 | 0 |
| Oracle WebLogic Server | 21.4 | 1 | 0 |
| Larry Ellison | 21.4 | 1 | 0 |
| Dave Raggett | 21.4 | 1 | 0 |
| Turtle | 21.4 | 1 | 0 |
| Jakarta Transactions | 21.4 | 1 | 0 |
| Nature Portfolio | 21.4 | 1 | 0 |
| Jakarta Server Pages | 21.4 | 1 | 0 |
| Java Platform, Micro Edition | 21.4 | 1 | 0 |
| Q220674 | 21.4 | 1 | 0 |
| Oracle Financial Services Software | 21.4 | 1 | 0 |
| TopLink | 21.4 | 1 | 0 |
| Allure | 21.4 | 1 | 0 |
| Mobile Information Device Profile | 21.4 | 1 | 0 |
| W3C Amaya | 21.4 | 1 | 0 |
| American Psychological Association | 21.4 | 1 | 0 |
| Q475488 | 21.4 | 1 | 0 |
| Apache Software Foundation | 21.4 | 1 | 0 |
| Compound Document Format | 21.4 | 1 | 0 |
| Allergan, Inc. | 21.4 | 1 | 0 |
| RDFa | 21.4 | 1 | 0 |
| Medicare | 21.4 | 1 | 0 |
| CERN httpd | 21.4 | 1 | 0 |
| Nature Communications | 21.4 | 1 | 0 |
| WorldWideWeb | 21.4 | 1 | 0 |
| Apache License | 21.4 | 1 | 0 |
| Bert Bos | 21.4 | 1 | 0 |
| Web Accessibility Initiative | 21.4 | 1 | 0 |
| Nature Reviews Cancer | 21.4 | 1 | 0 |
| Art Technology Group | 21.4 | 1 | 0 |
| OStatus | 21.4 | 1 | 0 |
| Java Database Connectivity | 21.4 | 1 | 0 |
| Java Development Kit | 21.4 | 1 | 0 |
| Jakarta Messaging | 21.4 | 1 | 0 |
| Berkeley DB | 21.4 | 1 | 0 |
| JRockit | 21.4 | 1 | 0 |
| K virtual machine | 21.4 | 1 | 0 |
| MathML | 21.4 | 1 | 0 |
| Web Ontology Language | 21.4 | 1 | 0 |
| XQuery | 21.4 | 1 | 0 |
| Allergan plc | 21.4 | 1 | 0 |
| libwww | 21.4 | 1 | 0 |
| British Journal of Pharmacology | 21.4 | 1 | 0 |
| Java Foundation Classes | 21.4 | 1 | 0 |
| Better Business Bureau | 21.4 | 1 | 0 |
| Massimo Marchiori | 21.4 | 1 | 0 |
| WebSub | 21.4 | 1 | 0 |
| Clinical Pharmacology & Therapeutics | 21.4 | 1 | 0 |
| Confluence | 21.4 | 1 | 0 |
| Java Advanced Imaging | 21.4 | 1 | 0 |
| Oracle iPlanet Web Server | 21.4 | 1 | 0 |
| Jira | 21.4 | 1 | 0 |
| OpenSPARC | 21.4 | 1 | 0 |
| Essbase | 21.4 | 1 | 0 |
| Javadoc | 21.4 | 1 | 0 |
| Notation3 | 21.4 | 1 | 0 |
| Cell Research | 21.4 | 1 | 0 |
| Nature Neuroscience | 21.4 | 1 | 0 |
| JavaOne | 21.4 | 1 | 0 |
| Oracle Cloud File System | 21.4 | 1 | 0 |
| Java Media Framework | 21.4 | 1 | 0 |
| RDF Schema | 21.4 | 1 | 0 |
| Storage Technology Corporation | 21.4 | 1 | 0 |
| Line Mode Browser | 21.4 | 1 | 0 |
| Oracle Application Development Framework | 21.4 | 1 | 0 |
| Nature Biotechnology | 21.4 | 1 | 0 |
| PeopleSoft | 21.4 | 1 | 0 |
| Oracle Call Interface | 21.4 | 1 | 0 |
| CVS Pharmacy | 21.4 | 1 | 0 |
| Nature Reviews Urology | 21.4 | 1 | 0 |
| Nature Reviews Neuroscience | 21.4 | 1 | 0 |
| Nature Reviews Gastroenterology & Hepatology | 21.4 | 1 | 0 |
| Nature India | 21.4 | 1 | 0 |
| Primavera | 21.4 | 1 | 0 |
| Tuxedo | 21.4 | 1 | 0 |
| SVG Working Group | 21.4 | 1 | 0 |
| Scientific American Mind | 21.4 | 1 | 0 |
| Molecular Systems Biology | 21.4 | 1 | 0 |
| JavaFX | 21.4 | 1 | 0 |
| SKOS | 21.4 | 1 | 0 |
| Sephora | 21.4 | 1 | 0 |
| JD Edwards | 21.4 | 1 | 0 |
| Oracle Developer Studio | 21.4 | 1 | 0 |
| Clinique Laboratories, LLC | 21.4 | 1 | 0 |
| Oracle Grid Engine | 21.4 | 1 | 0 |
| Agile Software Corporation | 21.4 | 1 | 0 |
| Neoplasia | 21.4 | 1 | 0 |
| Evaluation and Report Language | 21.4 | 1 | 0 |
| Journal of Investigative Dermatology | 21.4 | 1 | 0 |
| Nature Protocols | 21.4 | 1 | 0 |
| Sun Java Communications Suite | 21.4 | 1 | 0 |
| Java Platform | 21.4 | 1 | 0 |
| Oracle Spatial | 21.4 | 1 | 0 |
| WebMD | 21.4 | 1 | 0 |
| semantic triple | 21.4 | 1 | 0 |
| Annotea | 21.4 | 1 | 0 |
| HTML 4.0 | 21.4 | 1 | 0 |
| Open Digital Rights Language | 21.4 | 1 | 0 |
| Oracle Applications | 21.4 | 1 | 0 |
| Polymer Journal | 21.4 | 1 | 0 |
| Weaving the Web | 21.4 | 1 | 0 |
| TimesTen | 21.4 | 1 | 0 |
| Oracle Exadata | 21.4 | 1 | 0 |
| Oracle Exalogic | 21.4 | 1 | 0 |
| JD Edwards EnterpriseOne | 21.4 | 1 | 0 |
| Jinitiator | 21.4 | 1 | 0 |
| Oracle VM Server for SPARC | 21.4 | 1 | 0 |
| Oracle OpenWorld | 21.4 | 1 | 0 |
| Oracle Rdb | 21.4 | 1 | 0 |
| Solaris Cluster | 21.4 | 1 | 0 |
| Erwise | 21.4 | 1 | 0 |
| American Academy of Allergy, Asthma, and Immunology | 21.4 | 1 | 0 |
| American Academy of Dermatology | 21.4 | 1 | 0 |
| American Psychologist | 21.4 | 1 | 0 |
| American Society of Plastic Surgeons | 21.4 | 1 | 0 |
| Arena | 21.4 | 1 | 0 |
| Asian American Journal of Psychology | 21.4 | 1 | 0 |
| Bamboo | 21.4 | 1 | 0 |
| Behavioral Neuroscience | 21.4 | 1 | 0 |
| BigMachines | 21.4 | 1 | 0 |
| Bluemercury | 21.4 | 1 | 0 |
| Canyon Ranch | 21.4 | 1 | 0 |
| Consulting Psychology Journal: Practice and Research | 21.4 | 1 | 0 |
| CrowdTwist | 21.4 | 1 | 0 |
| Crucible | 21.4 | 1 | 0 |
| Families, Systems and Health | 21.4 | 1 | 0 |
| FatWire | 21.4 | 1 | 0 |
| FishEye | 21.4 | 1 | 0 |
| PsycINFO | 21.4 | 1 | 0 |
| HH-suite | 21.4 | 1 | 0 |
| HHpred / HHsearch | 21.4 | 1 | 0 |
| Heyday Records | 21.4 | 1 | 0 |
| HipChat | 21.4 | 1 | 0 |
| History of Psychology | 21.4 | 1 | 0 |
| Hyperion Planning | 21.4 | 1 | 0 |
| JIRA Studio | 21.4 | 1 | 0 |
| JSON-LD | 21.4 | 1 | 0 |
| Journal of Abnormal Psychology | 21.4 | 1 | 0 |
| Journal of Applied Psychology | 21.4 | 1 | 0 |
| Journal of Comparative and Physiological Psychology | 21.4 | 1 | 0 |
| Journal of Counseling Psychology | 21.4 | 1 | 0 |
| Journal of Diversity in Higher Education | 21.4 | 1 | 0 |
| Journal of Experimental Psychology | 21.4 | 1 | 0 |
| Journal of Experimental Psychology: Applied | 21.4 | 1 | 0 |
| Journal of Experimental Psychology: Learning, Memory, and Cognition | 21.4 | 1 | 0 |
| Journal of Family Psychology | 21.4 | 1 | 0 |
| Journal of Human Genetics | 21.4 | 1 | 0 |
| Kidney International | 21.4 | 1 | 0 |
| Law and Human Behavior | 21.4 | 1 | 0 |
| list of Apache Software Foundation projects | 21.4 | 1 | 0 |
| list of acquisitions by AOL | 21.4 | 1 | 0 |
| MedStar Health | 21.4 | 1 | 0 |
| Medicare Part D | 21.4 | 1 | 0 |
| Military Psychology | 21.4 | 1 | 0 |
| National Rehabilitation Hospital | 21.4 | 1 | 0 |
| Nextdoor | 21.4 | 1 | 0 |
| Oracle BI Publisher | 21.4 | 1 | 0 |
| Oracle Beehive | 21.4 | 1 | 0 |
| Oracle BPEL Process Manager | 21.4 | 1 | 0 |
| Oracle Data Mining | 21.4 | 1 | 0 |
| Oracle Designer | 21.4 | 1 | 0 |
| Oracle Discoverer | 21.4 | 1 | 0 |
| Oracle Enterprise Manager Ops Center | 21.4 | 1 | 0 |
| Oracle Enterprise Pack for Eclipse | 21.4 | 1 | 0 |
| Oracle NoSQL Database | 21.4 | 1 | 0 |
| Oracle Policy Automation | 21.4 | 1 | 0 |
| Oracle VDI | 21.4 | 1 | 0 |
| Oracle Multimedia | 21.4 | 1 | 0 |
| Peace and Conflict | 21.4 | 1 | 0 |
| Primavera Systems | 21.4 | 1 | 0 |
| Psychiatric Rehabilitation Journal | 21.4 | 1 | 0 |
| Psychological Methods | 21.4 | 1 | 0 |
| Psychology, Public Policy and Law | 21.4 | 1 | 0 |
| Psychomusicology: Music, Mind and Brain | 21.4 | 1 | 0 |
| Review of General Psychology | 21.4 | 1 | 0 |
| RightNow Technologies | 21.4 | 1 | 0 |
| SNReview | 21.4 | 1 | 0 |
| Schema for Object-Oriented XML | 21.4 | 1 | 0 |
| SkinCeuticals | 21.4 | 1 | 0 |
| Sun Java System Web Proxy Server | 21.4 | 1 | 0 |
| TOA Technologies | 21.4 | 1 | 0 |
| Taleo | 21.4 | 1 | 0 |
| The American Journal of Gastroenterology | 21.4 | 1 | 0 |
| The ISME Journal | 21.4 | 1 | 0 |
| The Journal of Antibiotics | 21.4 | 1 | 0 |
| Ulta Beauty | 21.4 | 1 | 0 |
| W3C Device Description Working Group | 21.4 | 1 | 0 |
| Washington Hospital Center | 21.4 | 1 | 0 |
| Web SQL Database | 21.4 | 1 | 0 |
| XHTML+MathML+SVG | 21.4 | 1 | 0 |
| Yext | 21.4 | 1 | 0 |
| Zocdoc | 21.4 | 1 | 0 |
| Associating Style Sheets with XML documents | 21.4 | 1 | 0 |
| Massage Envy | 21.4 | 1 | 0 |
| Oracle VM | 21.4 | 1 | 0 |
| Shadow DOM | 21.4 | 1 | 0 |
| Apache Software License 2.0 | 21.4 | 1 | 0 |
| Experimental and Clinical Psychopharmacology | 21.4 | 1 | 0 |
| Psychology of Men and Masculinity | 21.4 | 1 | 0 |
| Journal of Exposure Analysis and Environmental Epidemiology | 21.4 | 1 | 0 |
| Modern Pathology | 21.4 | 1 | 0 |
| International Journal of Oral Science | 21.4 | 1 | 0 |
| Genes and Immunity | 21.4 | 1 | 0 |
| Journal of Human Hypertension | 21.4 | 1 | 0 |
| Nature Clinical Practice Endocrinology and Metabolism | 21.4 | 1 | 0 |
| Nature Clinical Practice Neurology | 21.4 | 1 | 0 |
| Nature Clinical Practice Nephrology | 21.4 | 1 | 0 |
| Nature Clinical Practice Oncology | 21.4 | 1 | 0 |
| Nature Clinical Practice Rheumatology | 21.4 | 1 | 0 |
| Spinal Cord | 21.4 | 1 | 0 |
| Bone Marrow Transplantation. Supplement | 21.4 | 1 | 0 |
| Clinical Psychology: Science and Practice | 21.4 | 1 | 0 |
| Experimental and Molecular Medicine | 21.4 | 1 | 0 |
| Lab Animal | 21.4 | 1 | 0 |
| Public Health | 21.4 | 1 | 0 |
| Molecular Therapy | 21.4 | 1 | 0 |
| Journal of Clinical Hypertension | 21.4 | 1 | 0 |
| Web Rule Language | 21.4 | 1 | 0 |
| DCAT | 21.4 | 1 | 0 |
| Sun Management Center | 21.4 | 1 | 0 |
| Webmention Recommendation | 21.4 | 1 | 0 |
| Beauty Brands | 21.4 | 1 | 0 |
| Oracle BPA Suite | 21.4 | 1 | 0 |
| WebID | 21.4 | 1 | 0 |
| Tacit Software | 21.4 | 1 | 0 |
| APA Distinguished Scientific Award for the Applications of Psychology | 21.4 | 1 | 0 |
| APA Award for Distinguished Professional Contributions to Applied Research | 21.4 | 1 | 0 |
| APA Award for Distinguished Scientific Contributions to Psychology | 21.4 | 1 | 0 |
| PeopleTools | 21.4 | 1 | 0 |
| Apache Software License, Version 1.1 | 21.4 | 1 | 0 |
| opensource.com | 21.4 | 1 | 0 |
| Duke | 21.4 | 1 | 0 |
| Encrypted Media Extensions | 21.4 | 1 | 0 |
| Bitbucket Data Center | 21.4 | 1 | 0 |
| Journal of Perinatology | 21.4 | 1 | 0 |
| BDJ Team | 21.4 | 1 | 0 |
| ClassPass | 21.4 | 1 | 0 |
| NPG Asia Materials | 21.4 | 1 | 0 |
| Web Compatibility Test for Mobile Browsers | 21.4 | 1 | 0 |
| Dermstore | 21.4 | 1 | 0 |
| Arthur W. Staats Lecture for Unifying Psychology | 21.4 | 1 | 0 |
| Prevention & Treatment | 21.4 | 1 | 0 |
| Australopithecus africanus: The Man-Ape of South Africa | 21.4 | 1 | 0 |
| APA International Humanitarian Award | 21.4 | 1 | 0 |
| RealSelf | 21.4 | 1 | 0 |
| Stellent | 21.4 | 1 | 0 |
| Nature Microbiology | 21.4 | 1 | 0 |
| APA Award for Outstanding Lifetime Contributions to Psychology | 21.4 | 1 | 0 |
| Web Authentication Working Group | 21.4 | 1 | 0 |
| Outstanding International Psychologist Award | 21.4 | 1 | 0 |
| Timed Text Markup Language | 21.4 | 1 | 0 |
| Paraplegia | 21.4 | 1 | 0 |
| International journal of obesity supplements | 21.4 | 1 | 0 |
| The British Journal of Cancer. Supplement | 21.4 | 1 | 0 |
| The Hematology Journal | 21.4 | 1 | 0 |
| Cellular and Molecular Immunology | 21.4 | 1 | 0 |
| The journal of investigative dermatology. Symposium proceedings | 21.4 | 1 | 0 |
| Journal of applied research in memory and cognition | 21.4 | 1 | 0 |
| Nature Structural Biology | 21.4 | 1 | 0 |
| Kidney International. Supplement | 21.4 | 1 | 0 |
| Kidney International Supplements | 21.4 | 1 | 0 |
| Leukemia supplements | 21.4 | 1 | 0 |
| Apache Software License, Version 1.0 | 21.4 | 1 | 0 |
| Bio/technology | 21.4 | 1 | 0 |
| Journal of consulting psychology | 21.4 | 1 | 0 |
| Journal of experimental psychology | 21.4 | 1 | 0 |
| Nature: New Biology | 21.4 | 1 | 0 |
| Cultural diversity and mental health | 21.4 | 1 | 0 |
| Family systems medicine | 21.4 | 1 | 0 |
| Journal of comparative psychology | 21.4 | 1 | 0 |
| Evidence-based dentistry | 21.4 | 1 | 0 |
| Nature reports. stem cells | 21.4 | 1 | 0 |
| American journal of gastroenterology supplements (Print) | 21.4 | 1 | 0 |
| Molecular Therapy. Nucleic acids | 21.4 | 1 | 0 |
| BoneKEy reports | 21.4 | 1 | 0 |
| Emerging Microbes & Infections | 21.4 | 1 | 0 |
| CPT: pharmacometrics & systems pharmacology | 21.4 | 1 | 0 |
| Protocol exchange | 21.4 | 1 | 0 |
| Molecular Therapy. Methods & Clinical Development | 21.4 | 1 | 0 |
| Scientific Data | 21.4 | 1 | 0 |
| Clinical & translational immunology | 21.4 | 1 | 0 |
| Translational issues in psychological science | 21.4 | 1 | 0 |
| NPJ schizophrenia | 21.4 | 1 | 0 |
| Motivation science | 21.4 | 1 | 0 |
| Cell discovery | 21.4 | 1 | 0 |
| Cell Death Discovery | 21.4 | 1 | 0 |
| NPJ biofilms and microbiomes | 21.4 | 1 | 0 |
| Human Genome Variation | 21.4 | 1 | 0 |
| Molecular therapy oncolytics | 21.4 | 1 | 0 |
| Stigma and health | 21.4 | 1 | 0 |
| NPJ systems biology and applications | 21.4 | 1 | 0 |
| Practice innovations (Washington, D.C.) | 21.4 | 1 | 0 |
| Spinal cord series and cases | 21.4 | 1 | 0 |
| NPG Asia materials | 21.4 | 1 | 0 |
| NPJ genomic medicine | 21.4 | 1 | 0 |
| NPJ science of learning | 21.4 | 1 | 0 |
| Palgrave Communications | 21.4 | 1 | 0 |
| Nature reviews. Materials | 21.4 | 1 | 0 |
| Enterocolitis in children with developmental disorders | 21.4 | 1 | 0 |
| MINDBODY | 21.4 | 1 | 0 |
| Minimum information requested in the annotation of biochemical models (MIRIAM) | 21.4 | 1 | 0 |
| MediaStream Processing API | 21.4 | 1 | 0 |
| Heritage Science | 21.4 | 1 | 0 |
| Nature: Physical Science | 21.4 | 1 | 0 |
| Eric G. Prud'hommeaux | 21.4 | 1 | 0 |
| Oracle Corporation UK | 21.4 | 1 | 0 |
| Oracle (Israel) | 21.4 | 1 | 0 |
| SHACL | 21.4 | 1 | 0 |
| Shape Expressions | 21.4 | 1 | 0 |
| Core organization ontology | 21.4 | 1 | 0 |
| Mathematical Markup Language (MathML) Version 2.0 (Second Edition) | 21.4 | 1 | 0 |
| Forefront of Dermatology | 21.4 | 1 | 0 |
| Linked Data Notifications | 21.4 | 1 | 0 |
| Oracle (Canada) | 21.4 | 1 | 0 |
| Oracle (India) | 21.4 | 1 | 0 |
| SPARQL 1.1 Protocol | 21.4 | 1 | 0 |
| N-Quads | 21.4 | 1 | 0 |
| Web Annotation Data Model | 21.4 | 1 | 0 |
| Intrinsic honesty and the prevalence of rule violations across societies | 21.4 | 1 | 0 |
| HTML 3.2 | 21.4 | 1 | 0 |
| Nature Machine Intelligence | 21.4 | 1 | 0 |
| Yellowstone National Park | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| rate | 20.0 | 0 | 1 |
| exfoliation | 20.0 | 0 | 1 |
| David Feldman | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Fritillaria recurva | 20.0 | 0 | 1 |
| As Long as You're Near Me | 20.0 | 0 | 1 |
| chemical peel | 20.0 | 0 | 1 |
| Close to Home, season 2 | 20.0 | 0 | 1 |
| Close to Home, season 1 | 20.0 | 0 | 1 |
| EBooking | 20.0 | 0 | 1 |
| Be Near Me | 20.0 | 0 | 1 |
| benefit–cost ratio | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Etix | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| IQAir | 20.0 | 0 | 1 |
| I Want You Near Me | 20.0 | 0 | 1 |
| list of Close to Home (2005 TV series) episodes | 20.0 | 0 | 1 |
| Q6592867 | 20.0 | 0 | 1 |
| Naama Schendar | 20.0 | 0 | 1 |
| Momentum | 20.0 | 0 | 1 |
| Never Back Down | 20.0 | 0 | 1 |
| Picture Perfect | 20.0 | 0 | 1 |
| Rapaport Diamond Report | 20.0 | 0 | 1 |
| Platelet-rich fibrin matrix | 20.0 | 0 | 1 |
| So Much Water So Close to Home | 20.0 | 0 | 1 |
| Too Close to Home | 20.0 | 0 | 1 |
| Travel to Romantis | 20.0 | 0 | 1 |
| Value for Money | 20.0 | 0 | 1 |
| Whenever You're Near Me | 20.0 | 0 | 1 |
| Category:Close to Home (band) albums | 20.0 | 0 | 1 |
| Q9278581 | 20.0 | 0 | 1 |
| Solanka Park in Inowrocław | 20.0 | 0 | 1 |
| day spa | 20.0 | 0 | 1 |
| price list | 20.0 | 0 | 1 |
| Nearby | 20.0 | 0 | 1 |
| Amma Unavagam | 20.0 | 0 | 1 |
| Tregele | 20.0 | 0 | 1 |
| Edison and Swan Electric Light Company | 20.0 | 0 | 1 |
| ClickBus | 20.0 | 0 | 1 |
| GolfNow | 20.0 | 0 | 1 |
| FromAtoB.com | 20.0 | 0 | 1 |
| So Much Water So Close to Home | 20.0 | 0 | 1 |
| Mystic shadow | 20.0 | 0 | 1 |
| On LHs Seat near Me | 20.0 | 0 | 1 |
| Value for Money and Lower Taxes | 20.0 | 0 | 1 |
| Dermal filler | 20.0 | 0 | 1 |
| Which health technologies should be funded? A prioritization framework based explicitly on value for money | 20.0 | 0 | 1 |
| Online CBT I: Bridging the Gap Between Eliza and Modern Online CBT Treatment Packages | 20.0 | 0 | 1 |
| Diviac | 20.0 | 0 | 1 |
| Keeping it close to home with imby | 20.0 | 0 | 1 |
| Too Close to Home | 20.0 | 0 | 1 |
| The Spoils | 20.0 | 0 | 1 |
| Does performance-based financing increase value for money in low- and middle- income countries? A systematic review | 20.0 | 0 | 1 |
| Should it be a trigger to establish a medical regulatory body in Korea?: A case of hepatitis C epidemic due to reuse of disposable syringes in a local clinic in Seoul | 20.0 | 0 | 1 |
| Social Return on Investment (SROI) methodology to account for value for money of public health interventions: a systematic review | 20.0 | 0 | 1 |
| Too Close to Home | 20.0 | 0 | 1 |
| Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS | 20.0 | 0 | 1 |
| Botox treatment in adductor spasmodic dysphonia: a meta-analysis | 20.0 | 0 | 1 |
| Relationship between delayed reactions to dermal fillers and biofilms: facts and considerations | 20.0 | 0 | 1 |
| Facial Treatment Preferences in Aesthetically Aware Women | 20.0 | 0 | 1 |
| Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers | 20.0 | 0 | 1 |
| Periorbital Phenol-Croton Oil Chemical Peel in Conjunction with Blepharoplasty: An Evolving Technique for Periorbital Facial Rejuvenation | 20.0 | 0 | 1 |
| A Case of Lichen Planus Pigmentosus with Facial Dyspigmentation Responsive to Combination Therapy with Chemical Peels and Topical Retinoids | 20.0 | 0 | 1 |
| A Split-Face Evaluation to Assess the Efficacy of a Hydrolyzed Roe Cream in the Reduction of Erythema Following Chemical Peel | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Value for Money | 20.0 | 0 | 1 |
| Complications of Injectable Fillers, Part 2: Vascular Complications | 20.0 | 0 | 1 |
| Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions | 20.0 | 0 | 1 |
| Optimed Eye and Laser Clinic | 20.0 | 0 | 1 |
| Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money | 20.0 | 0 | 1 |
| Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience | 20.0 | 0 | 1 |
| Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience | 20.0 | 0 | 1 |
| Is a Mass Prevention and Control Program for Pandemic (H1N1) 2009 Good Value for Money? Evidence from the Chinese Experience | 20.0 | 0 | 1 |
| Do you know where your fillers go? An ultrastructural investigation of the lips | 20.0 | 0 | 1 |
| 'Open for business': do open-access psychiatry journals provide value for money? | 20.0 | 0 | 1 |
| Screening for people with diabetes mellitus for poor blood glucose control in an ophthalmological laser clinic | 20.0 | 0 | 1 |
| Treatment of upper lip wrinkles: a comparison of 950 microsec dwell time carbon dioxide laser with unoccluded Baker's phenol chemical peel | 20.0 | 0 | 1 |
| Optical coherence tomography as a tool for real-time visual feedback and biomechanical assessment of dermal filler injections: preliminary results in a pig skin model | 20.0 | 0 | 1 |
| The histologic evaluation of pulsed carbon dioxide laser resurfacing versus phenol chemical peels in vivo | 20.0 | 0 | 1 |
| Breakthroughs in US dermal fillers for facial soft-tissue augmentation | 20.0 | 0 | 1 |
| Comparison of the laser and phenol chemical peel in facial skin resurfacing | 20.0 | 0 | 1 |
| Chemical peel of nonfacial skin using glycolic acid gel augmented with TCA and neutralized based on visual staging | 20.0 | 0 | 1 |
| Facial skin rejuvenation: laser resurfacing or chemical peel: choose your weapon | 20.0 | 0 | 1 |
| Chemical peels. | 20.0 | 0 | 1 |
| Update on Chemical Peels | 20.0 | 0 | 1 |
| Effect of physician specialist alternative payment plans on administrative health data in Calgary: a validation study | 20.0 | 0 | 1 |
| Chemical peels: their place within the range of resurfacing techniques | 20.0 | 0 | 1 |
| Surgical pearl: the use of a teaspoon during dermal filler injection | 20.0 | 0 | 1 |
| Delayed Adverse Subcutaneous Reaction to a New Family of Hyaluronic Acid Dermal Fillers With Clinical, Ultrasound, and Histologic Correlation | 20.0 | 0 | 1 |
| Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study | 20.0 | 0 | 1 |
| Histopathologic Changes of the Eyelid Skin Following Trichloroacetic Acid Chemical Peel | 20.0 | 0 | 1 |
| The art of the trichloroacetic acid chemical peel | 20.0 | 0 | 1 |
| Demographic study of port wine stain patients attending a laser clinic: family history, prevalence of naevus anaemicus and results of prior treatment | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| New classification scheme for laser resurfacing and chemical peels: modifications for the different ethnic groups | 20.0 | 0 | 1 |
| A single-blinded randomised controlled study to determine the efficacy of Omnilux Revive facial treatment in skin rejuvenation | 20.0 | 0 | 1 |
| Dermal fillers: complications and informed consent | 20.0 | 0 | 1 |
| Coral reef fish larvae settle close to home | 20.0 | 0 | 1 |
| Chemical peels | 20.0 | 0 | 1 |
| Adverse reactions to dermal fillers: a review of European experiences | 20.0 | 0 | 1 |
| Advances in deep chemical peels. | 20.0 | 0 | 1 |
| Avoiding and treating dermal filler complications | 20.0 | 0 | 1 |
| Complications after dermal fillers and their treatment | 20.0 | 0 | 1 |
| Data briefing. Patients opting for care close to home. | 20.0 | 0 | 1 |
| Value for money: protecting endangered species on Danish heathland. | 20.0 | 0 | 1 |
| Juvéderm: a hyaluronic acid dermal filler. | 20.0 | 0 | 1 |
| Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. | 20.0 | 0 | 1 |
| The science of hyaluronic acid dermal fillers | 20.0 | 0 | 1 |
| Twelve-month persistency of a novel ribose-cross-linked collagen dermal filler | 20.0 | 0 | 1 |
| Incorporating a medical spa into a physician-run practice | 20.0 | 0 | 1 |
| Procedures offered in the medical spa environment | 20.0 | 0 | 1 |
| Medical-legal considerations in the medical spa environment | 20.0 | 0 | 1 |
| Chemical peels, dermabrasion, and laser therapy | 20.0 | 0 | 1 |
| Foreign body granulomas after all injectable dermal fillers: part 2. Treatment options | 20.0 | 0 | 1 |
| Tackling climate change close to home: mobile breast screening as a model | 20.0 | 0 | 1 |
| The use of Dermicol-P35 dermal filler for nonsurgical rhinoplasty | 20.0 | 0 | 1 |
| Correction of tear trough deformity with novel porcine collagen dermal filler (Dermicol-P35). | 20.0 | 0 | 1 |
| Does expenditure on pharmaceuticals give good value for money?: current evidence and policy implications | 20.0 | 0 | 1 |
| Antimicrobial Stewardship Initiatives Throughout Europe: Proven Value for Money | 20.0 | 0 | 1 |
| Package pricing roils cardiac, orthopedic services. | 20.0 | 0 | 1 |
| Making the right choices: attaining predictable aesthetic results with dermal fillers | 20.0 | 0 | 1 |
| Private financing options for long-term care | 20.0 | 0 | 1 |
| Treatment of lateral canthal rhytides with a medium depth chemical peel with or without pretreatment with onabotulinum toxin type A: a randomized control trial | 20.0 | 0 | 1 |
| A review of value for money in sterile services. | 20.0 | 0 | 1 |
| Value for money in the health sector: the contribution of primary health care | 20.0 | 0 | 1 |
| Health economics evidence for medical nutrition: are these interventions value for money in integrated care? | 20.0 | 0 | 1 |
| Preventing the Complications Associated with the Use of Dermal Fillers in Facial Aesthetic Procedures: An Expert Group Consensus Report | 20.0 | 0 | 1 |
| Are weekend inpatient rehabilitation services value for money? An economic evaluation alongside a randomized controlled trial with a 30 day follow up | 20.0 | 0 | 1 |
| Current Chemical Peels and Other Resurfacing Techniques | 20.0 | 0 | 1 |
| Value for money and the Quality and Outcomes Framework in primary care in the UK NHS. | 20.0 | 0 | 1 |
| Persistence of Nasolabial Fold Correction with a Hyaluronic Acid Dermal Filler with Retreatment: Results of an 18-Month Extension Study | 20.0 | 0 | 1 |
| Private finance and "value for money" in NHS hospitals: a policy in search of a rationale? | 20.0 | 0 | 1 |
| NHS Direct audited. NHS Direct is value for money and improving | 20.0 | 0 | 1 |
| Was attending the conference worth value for money? | 20.0 | 0 | 1 |
| Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability | 20.0 | 0 | 1 |
| Current state of acne treatment: highlighting lasers, photodynamic therapy, and chemical peels | 20.0 | 0 | 1 |
| Effectiveness evaluation of two volumizing hyaluronic acid dermal fillers in a controlled, randomized, double-blind, split-face clinical study | 20.0 | 0 | 1 |
| Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of moderate nasolabial folds: 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study | 20.0 | 0 | 1 |
| Dermal Fillers: Do's and Dont's | 20.0 | 0 | 1 |
| Understanding financing options for PACS implementation. Picture archiving and communication systems | 20.0 | 0 | 1 |
| The use of a contact cooling device to reduce pain and ecchymosis associated with dermal filler injections | 20.0 | 0 | 1 |
| Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing | 20.0 | 0 | 1 |
| Severe Acute Local Reactions to a Hyaluronic Acid-derived Dermal Filler. | 20.0 | 0 | 1 |
| A prospective, open‐label, multicenter, observational, postmarket study of the use of a 15 mg/mL hyaluronic acid dermal filler in the lips | 20.0 | 0 | 1 |
| Medium-depth chemical peels | 20.0 | 0 | 1 |
| A review of dermal fillers in facial plastic surgery | 20.0 | 0 | 1 |
| Use of component analyses to identify active variables in treatment packages for children with feeding disorders | 20.0 | 0 | 1 |
| Evaluation of client preference for function-based treatment packages | 20.0 | 0 | 1 |
| Using pretreatment and posttreatment assessments to enhance and evaluate existing treatment packages | 20.0 | 0 | 1 |
| A brief component analysis of potential treatment packages in an outpatient clinic setting with young children | 20.0 | 0 | 1 |
| What is the value for money of medicines? A registry study | 20.0 | 0 | 1 |
| Psychology should list empirically supported principles of change (ESPs) and not credential trademarked therapies or other treatment packages | 20.0 | 0 | 1 |
| Trends in the Use of Neurotoxins and Dermal Fillers by US Physicians | 20.0 | 0 | 1 |
| Non-ablative 1540 fractional laser: how far could it help injection lipolysis and dermal fillers in lower-face rejuvenation? A randomized controlled trial. | 20.0 | 0 | 1 |
| Dermal filler materials and botulin toxin | 20.0 | 0 | 1 |
| Secondary prevention of osteoporosis in non-neck of femur fragility fractures: is it value for money? A retrospective, prospective and cross-sectional cohort study | 20.0 | 0 | 1 |
| Some new injectable dermal filler materials: Hylaform, Restylane, and Artecoll | 20.0 | 0 | 1 |
| Safety of dermal fillers. | 20.0 | 0 | 1 |
| A minimum price per unit of alcohol: a focus group study to investigate public opinion concerning UK government proposals to introduce new price controls to curb alcohol consumption. | 20.0 | 0 | 1 |
| The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups | 20.0 | 0 | 1 |
| Dermal filler injection: a novel approach for limiting infarct expansion | 20.0 | 0 | 1 |
| Laser skin resurfacing, chemical peels, and other cutaneous treatments of the brow and upper lid. | 20.0 | 0 | 1 |
| Efficacy and safety of a new superficial chemical peel using alpha-hydroxy acid, vitamin C and oxygen for melasma | 20.0 | 0 | 1 |
| Knowledge and attitude of dentists towards the use of botulinum toxin and dermal fillers in dentistry, Riyadh, Saudi Arabia. | 20.0 | 0 | 1 |
| Dermal fillers for the treatment of tear trough deformity: A review of anatomy, treatment techniques, and their outcomes | 20.0 | 0 | 1 |
| Chemical peels for melasma in dark-skinned patients | 20.0 | 0 | 1 |
| A membership program for residents and interns: a report to the council by the commission on communications | 20.0 | 0 | 1 |
| Facial granulomas secondary to injection of semi-permanent cosmetic dermal filler containing acrylic hydrogel particles | 20.0 | 0 | 1 |
| Lip Augmentation Dermal Filler Reactions, Histopathologic Features | 20.0 | 0 | 1 |
| Chemical peels: an overview | 20.0 | 0 | 1 |
| Not All Larvae Stay Close to Home: Insights into Marine Population Connectivity with a Focus on the Brown Surgeonfish (Acanthurus nigrofuscus) | 20.0 | 0 | 1 |
| A Review of the Metabolism of 1,4-Butanediol Diglycidyl Ether-Crosslinked Hyaluronic Acid Dermal Fillers | 20.0 | 0 | 1 |
| The characteristics of bacterial nanocellulose gel releasing silk sericin for facial treatment | 20.0 | 0 | 1 |
| The world as the new local clinic: A critical analysis of three discourses of global medical competency | 20.0 | 0 | 1 |
| Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration? | 20.0 | 0 | 1 |
| Standard guidelines of care for chemical peels. | 20.0 | 0 | 1 |
| New-generation filler based on cross-linked carboxymethylcellulose: study of 350 patients with 3-year follow-up | 20.0 | 0 | 1 |
| What makes medical graduates practise close to home? | 20.0 | 0 | 1 |
| Botox treatment for vaginismus | 20.0 | 0 | 1 |
| Facial skin rejuvenation: Ablative laser resurfacing, chemical peels, or photodynamic therapy? Facts and controversies | 20.0 | 0 | 1 |
| Chemical peels: panel discussion | 20.0 | 0 | 1 |
| Experimental dermatological surgery: An animal model for developing skills with dermal fillers | 20.0 | 0 | 1 |
| A prospective, observational study of the volumizing effect of open-label aesthetic use of Juvéderm®VOLUMA®with Lidocaine in mid-face area | 20.0 | 0 | 1 |
| A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars | 20.0 | 0 | 1 |
| Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes | 20.0 | 0 | 1 |
| An Open-Label Uncontrolled, Multicenter Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess VOLUME in the Treatment of Nasolabial Folds | 20.0 | 0 | 1 |
| Understanding the safety and tolerability of facial filling therapeutics | 20.0 | 0 | 1 |
| Diagnosis and management of dermal filler complications in the perioral region | 20.0 | 0 | 1 |
| Close to home: an analysis of the relationship between location of residence and location of injury. | 20.0 | 0 | 1 |
| Dental Procedures: Is it a Risk Factor for Injectable Dermal Fillers? | 20.0 | 0 | 1 |
| Avoiding the “Danger Zones” When Injecting Dermal Fillers and Volume Enhancers | 20.0 | 0 | 1 |
| The life cycles and biological end pathways of dermal fillers | 20.0 | 0 | 1 |
| Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler | 20.0 | 0 | 1 |
| Treatment of Delayed Reactions to Dermal Fillers | 20.0 | 0 | 1 |
| Value for money of changing healthcare services? Economic evaluation of quality improvement | 20.0 | 0 | 1 |
| Physician supervision of medical spas: Georgia's new laws on cosmetic lasers | 20.0 | 0 | 1 |
| Ocular adverse effects after facial cosmetic procedures: a review of case reports | 20.0 | 0 | 1 |
| Prioritizing investments in health: can we assess potential value for money? | 20.0 | 0 | 1 |
| Avoiding malar edema during midface/cheek augmentation with dermal fillers | 20.0 | 0 | 1 |
| Identification of Best Practices for Resident Aesthetic Clinics in Plastic Surgery Training: The ACAPS National Survey | 20.0 | 0 | 1 |
| A comparison of the efficacy, safety, and longevity of two different hyaluronic acid dermal fillers in the treatment of severe nasolabial folds: a multicenter, prospective, randomized, controlled, single-blind, within-subject study | 20.0 | 0 | 1 |
| Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines | 20.0 | 0 | 1 |
| Are surgical shoes providing value for money? | 20.0 | 0 | 1 |
| Dermal fillers. The next generation | 20.0 | 0 | 1 |
| Chemical peel treatments in dermatology | 20.0 | 0 | 1 |
| Treatment of Acne Vulgaris With Salicylic Acid Chemical Peel and Pulsed Dye Laser: A Split Face, Rater-Blinded, Randomized Controlled Trial | 20.0 | 0 | 1 |
| Assessing economics of treatments for gynecological cancer where clinical effectiveness meets value for money | 20.0 | 0 | 1 |
| Location of injected polymethylmethacrylate microspheres influences the onset of late adverse effects: an experimental and histopathologic study | 20.0 | 0 | 1 |
| Biopolymeric agents for skin wrinkle treatment | 20.0 | 0 | 1 |
| Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis? | 20.0 | 0 | 1 |
| Replacing dermal constituents lost through aging with dermal fillers | 20.0 | 0 | 1 |
| Combining Microfocused Ultrasound With Botulinum Toxin and Temporary and Semi-Permanent Dermal Fillers: Safety and Current Use. | 20.0 | 0 | 1 |
| Noninvasive Facial Rejuvenation. Part 3: Physician-Directed-Lasers, Chemical Peels, and Other Noninvasive Modalities | 20.0 | 0 | 1 |
| Which interventions offer best value for money in primary prevention of cardiovascular disease? | 20.0 | 0 | 1 |
| Cost-effectiveness: seeking value for money in lower extremity wound management. | 20.0 | 0 | 1 |
| Evaluation of the in vivo effects of various laser, light, or ultrasound modalities on human skin treated with a collagen and polymethylmethacrylate microsphere dermal filler product | 20.0 | 0 | 1 |
| Preventing, identifying, and managing cosmetic procedure complications, part 2: lasers and chemical peels | 20.0 | 0 | 1 |
| Facial Treatment Preferences Among Aesthetically Oriented Men. | 20.0 | 0 | 1 |
| Dermal fillers: pathophysiology, prevention and treatment of complications | 20.0 | 0 | 1 |
| An ophthalmologist's guide to chemical peels | 20.0 | 0 | 1 |
| Rejuvenation of the perioral and lip regions with two new dermal fillers: The Italian experience with Vycross™ Technology | 20.0 | 0 | 1 |
| Mycobacterium chelonae Facial Infections Following Injection of Dermal Filler | 20.0 | 0 | 1 |
| A national riparian restoration programme in New Zealand: Is it value for money? | 20.0 | 0 | 1 |
| Analysis of colonoscopic perforations at a local clinic and a tertiary hospital | 20.0 | 0 | 1 |
| Advocacy and people with learning disabilities in the UK: how can local funders find value for money? | 20.0 | 0 | 1 |
| Treatment of the ageing hand with dermal fillers | 20.0 | 0 | 1 |
| ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. | 20.0 | 0 | 1 |
| Adverse reactions to dermal fillers: review. | 20.0 | 0 | 1 |
| Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers | 20.0 | 0 | 1 |
| Calcium Hydroxylapatite Dermal Filler for Treatment of Dorsal Hand Volume Loss: Results From a 12-Month, Multicenter, Randomized, Blinded Trial | 20.0 | 0 | 1 |
| Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. | 20.0 | 0 | 1 |
| Investigation of Physical Properties of a Polycaprolactone Dermal Filler when Mixed with Lidocaine and Lidocaine/Epinephrine | 20.0 | 0 | 1 |
| Chemical peels and fillers-incorporating scientific evidence in clinical practice | 20.0 | 0 | 1 |
| Chemical peels for acne and acne scars in asians: Evidence based review | 20.0 | 0 | 1 |
| Dermal filler agents: a practical review | 20.0 | 0 | 1 |
| Combination of chemical peelings with botulinum toxin injections and dermal fillers | 20.0 | 0 | 1 |
| Ano-genital warts in consecutive male heterosexual patients referred to a CO2-laser clinic in Copenhagen | 20.0 | 0 | 1 |
| Consultants' study leave--value for money? | 20.0 | 0 | 1 |
| Use of a decision-analytic model in a health technology assessment: beyond measuring value for money | 20.0 | 0 | 1 |
| A case of acute pancreatitis: could this be caused by dermal filler injections? | 20.0 | 0 | 1 |
| Treating bleeding oesophageal varices with vasoactive agents: good value for money? | 20.0 | 0 | 1 |
| A peeler's thoughts on skin improvement with chemical peels and laser resurfacing. | 20.0 | 0 | 1 |
| Etiology, Prevention, and Management of Infectious Complications of Dermal Fillers | 20.0 | 0 | 1 |
| Treatment of periorbital wrinkles. A comparison of the SilkTouch carbon dioxide laser with a medium-depth chemical peel | 20.0 | 0 | 1 |
| Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment | 20.0 | 0 | 1 |
| CE offering--introductory offer Clostridium difficile associated disease (CDAD). | 20.0 | 0 | 1 |
| Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom | 20.0 | 0 | 1 |
| A Randomized, Evaluator-Blinded, Split-Face Comparison Study of the Efficacy and Safety of a Novel Mannitol Containing Monophasic Hyaluronic Acid Dermal Filler for the Treatment of Moderate to Severe Nasolabial Folds | 20.0 | 0 | 1 |
| Dermal fillers for facial soft tissue augmentation | 20.0 | 0 | 1 |
| Travelling far but staying close to home | 20.0 | 0 | 1 |
| Measuring value for money: a scoping review on economic evaluation of health information systems | 20.0 | 0 | 1 |
| Improved investment in mental health services: value for money? | 20.0 | 0 | 1 |
| U.S. physicians' views on financing options to expand health insurance coverage: a national survey | 20.0 | 0 | 1 |
| Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies--consensus recommendations | 20.0 | 0 | 1 |
| Perioral rejuvenation: restoration of attractiveness in aging females by minimally invasive procedures | 20.0 | 0 | 1 |
| Understanding, avoiding, and managing dermal filler complications | 20.0 | 0 | 1 |
| Technology approaches to the medical spa: art plus science equal rejuvenation | 20.0 | 0 | 1 |
| Medical spa marketing | 20.0 | 0 | 1 |
| Healthcare in Canada's North: Are We Getting Value for Money? | 20.0 | 0 | 1 |
| STYLAGE®: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature | 20.0 | 0 | 1 |
| Superficial chemical peels and microdermabrasion for acne vulgaris | 20.0 | 0 | 1 |
| The chemical peel. | 20.0 | 0 | 1 |
| Do modern total knee replacements offer better value for money? A health economic analysis | 20.0 | 0 | 1 |
| Longitudinal studies of gene-environment interaction in common diseases--good value for money? | 20.0 | 0 | 1 |
| Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care | 20.0 | 0 | 1 |
| Facial dermal fillers: selection of appropriate products and techniques | 20.0 | 0 | 1 |
| Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund | 20.0 | 0 | 1 |
| Comparative physical properties of hyaluronic acid dermal fillers | 20.0 | 0 | 1 |
| Expenditure and value for money: the challenge of implantable cardioverter defibrillators | 20.0 | 0 | 1 |
| The science and art of dermal fillers for soft-tissue augmentation. | 20.0 | 0 | 1 |
| The management of dermal filler complications | 20.0 | 0 | 1 |
| A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy | 20.0 | 0 | 1 |
| Chemical peels in aesthetic dermatology: an update 2009. | 20.0 | 0 | 1 |
| Clinical role and application of superficial chemical peels in today's practice. | 20.0 | 0 | 1 |
| The effect of incobotulinumtoxin a and dermal filler treatment on perception of age, health, and attractiveness of female faces | 20.0 | 0 | 1 |
| The risk of alar necrosis associated with dermal filler injection | 20.0 | 0 | 1 |
| Dermal fillers and combinations of fillers for facial rejuvenation | 20.0 | 0 | 1 |
| Bridging the resource gap: improving value for money in HIV/AIDS treatment | 20.0 | 0 | 1 |
| The science and art of hyaluronic acid dermal filler use in esthetic applications | 20.0 | 0 | 1 |
| Chemical peels: what's new and what isn't new but still works well | 20.0 | 0 | 1 |
| Increasing value for money in the Canadian healthcare system: new findings on the contribution of primary care services | 20.0 | 0 | 1 |
| Does a home-based strength and balance programme in people aged > or =80 years provide the best value for money to prevent falls? A systematic review of economic evaluations of falls prevention interventions | 20.0 | 0 | 1 |
| Chemical Peels for Darker Skin Types | 20.0 | 0 | 1 |
| The role of lidocaine, epinephrine, and flap elevation in wound healing after chemical peel | 20.0 | 0 | 1 |
| Value for money - recasting the problem in terms of dynamic access prioritisation | 20.0 | 0 | 1 |
| Biofilms: their role in dermal fillers | 20.0 | 0 | 1 |
| Update on botulinum toxin and dermal fillers | 20.0 | 0 | 1 |
| Dermal fillers Help patients put their best face forward | 20.0 | 0 | 1 |
| Histopathologic identification of dermal filler agents | 20.0 | 0 | 1 |
| The evidence for reducing the pain of administration of local anesthesia and cosmetic injectables | 20.0 | 0 | 1 |
| Expert Opinion: Efficacy of superficial chemical peels in active acne management – what can we learn from the literature today? Evidence‐based recommendations | 20.0 | 0 | 1 |
| What are the necessary practice competencies for two providers: dermal fillers and botulinum toxin type A injections? | 20.0 | 0 | 1 |
| Etiology, prevention, and treatment of dermal filler complications | 20.0 | 0 | 1 |
| A systematic review of dermal fillers for age‐related lines and wrinkles | 20.0 | 0 | 1 |
| Close to home: a history of Yale and Lyme disease | 20.0 | 0 | 1 |
| 3D Photography in the Objective Analysis of Volume Augmentation Including Fat Augmentation and Dermal Fillers | 20.0 | 0 | 1 |
| The euros and sense of stents: do we get value for money? | 20.0 | 0 | 1 |
| Five-year retrospective review of safety, injected volumes, and longevity of the hyaluronic acid Belotero Basic for facial treatments in 317 patients. | 20.0 | 0 | 1 |
| The basic science of dermal fillers: past and present Part I: background and mechanisms of action | 20.0 | 0 | 1 |
| The basic science of dermal fillers: past and present Part II: adverse effects | 20.0 | 0 | 1 |
| Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes | 20.0 | 0 | 1 |
| Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. | 20.0 | 0 | 1 |
| Nonsurgical Rhinoplasty Using Dermal Fillers | 20.0 | 0 | 1 |
| Autologous cell therapy: will it replace dermal fillers? | 20.0 | 0 | 1 |
| Innovations in Minimally Invasive Facial Treatments | 20.0 | 0 | 1 |
| Dermal fillers: facts and controversies | 20.0 | 0 | 1 |
| The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers | 20.0 | 0 | 1 |
| Nonsurgical Neck Laxity Correction | 20.0 | 0 | 1 |
| Dermal fillers in aesthetics: an overview of adverse events and treatment approaches | 20.0 | 0 | 1 |
| Do Chemical Peels Tighten the Skin? | 20.0 | 0 | 1 |
| Radiation Oncology research grants awarded by the Royal Australian and New Zealand College of Radiologists: Value for money? | 20.0 | 0 | 1 |
| Injectable Fillers: Review of Material and Properties | 20.0 | 0 | 1 |
| Use of Fillers in Rhinoplasty | 20.0 | 0 | 1 |
| Food Cent$ – implementing and evaluating a nutrition education project focusing on value for money | 20.0 | 0 | 1 |
| Dermal Fillers: An Update | 20.0 | 0 | 1 |
| Facial rejuvenation starts in the midface: three‐dimensional volumetric facial rejuvenation has beneficial effects on nontreated neighboring esthetic units | 20.0 | 0 | 1 |
| The Case for Synthetic Injectables | 20.0 | 0 | 1 |
| Occluded Baker-Gordon chemical peel: review and update | 20.0 | 0 | 1 |
| Hyaluronan in adipose tissue: Beyond dermal filler and therapeutic carrier | 20.0 | 0 | 1 |
| Upper Eyelid Filling With or Without Surgical Treatment | 20.0 | 0 | 1 |
| Value for money? An examination of the relationship between need and cost in intellectual disability services. | 20.0 | 0 | 1 |
| Mesotherapy, Microneedling, and Chemical Peels | 20.0 | 0 | 1 |
| Getting the best value for money in health care | 20.0 | 0 | 1 |
| A rapid review of the impact of commissioning on service use, quality, outcomes and value for money: implications for Australian policy | 20.0 | 0 | 1 |
| Preparation and characterization of a novel polysialic acid-hyaluronan graft copolymer potential as dermal filler. | 20.0 | 0 | 1 |
| Lip Injection Techniques Using Small-Particle Hyaluronic Acid Dermal Filler | 20.0 | 0 | 1 |
| A new tool to improve delivery of patient-engaged care and satisfaction in facial treatments: the Aesthetic Global Ranking Scale | 20.0 | 0 | 1 |
| Efficacy and safety of new dermal fillers | 20.0 | 0 | 1 |
| Delivering value for money | 20.0 | 0 | 1 |
| Chemical peel: a change in the routine | 20.0 | 0 | 1 |
| How to reveal people's preferences: Comparing time consistency and predictive power of multiple price list risk elicitation methods | 20.0 | 0 | 1 |
| Vibration Anesthesia for the Reduction of Pain with Facial Dermal Filler Injections | 20.0 | 0 | 1 |
| Botox treatment for migraine and chronic daily headache in adolescents | 20.0 | 0 | 1 |
| Obtaining best value for money in nutrition: an emerging new priority for the urban poor | 20.0 | 0 | 1 |
| How I treat. . . evanescent youth. Dating back using chemical peels | 20.0 | 0 | 1 |
| Financing structural interventions: going beyond HIV-only value for money assessments | 20.0 | 0 | 1 |
| Stool culture: are you getting value for money? | 20.0 | 0 | 1 |
| Increasing Primary Care Access Close to Home for Residents of Remote Communities in Northern Alberta. | 20.0 | 0 | 1 |
| Value for money and hospital pharmacists | 20.0 | 0 | 1 |
| Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer | 20.0 | 0 | 1 |
| Biophysical and biological characterization of a new line of hyaluronan-based dermal fillers: A scientific rationale to specific clinical indications | 20.0 | 0 | 1 |
| A case of diffuse alveolar hemorrhage associated with hyaluronic acid dermal fillers | 20.0 | 0 | 1 |
| Modelling the affordability and distributional implications of future health care financing options in South Africa | 20.0 | 0 | 1 |
| Value for money from HPV vaccination and cervical screening. | 20.0 | 0 | 1 |
| Homologous collagen dispersion (dermalogen) as a dermal filler: persistence and histology compared with bovine collagen | 20.0 | 0 | 1 |
| Dermal fillers: Tips to achieve successful outcomes | 20.0 | 0 | 1 |
| Close to Home: Employment Outcomes for Recent Radiation Oncology Graduates | 20.0 | 0 | 1 |
| The chemical peel | 20.0 | 0 | 1 |
| Child injury risks are close to home: parent psychosocial factors associated with child safety. | 20.0 | 0 | 1 |
| What treatment packages do UK physiotherapists use to treat postural control and mobility problems after stroke? | 20.0 | 0 | 1 |
| Lifestyle intervention: from cost savings to value for money. | 20.0 | 0 | 1 |
| Temporary polysaccharide dermal fillers: a model for persistence based on physical properties | 20.0 | 0 | 1 |
| Collagen-based dermal fillers: past, present, future | 20.0 | 0 | 1 |
| Assessment of a superficial chemical peel combined with a multimodal, hydroquinone-free skin brightener using in vivo reflectance confocal microscopy | 20.0 | 0 | 1 |
| Crosslinked hyaluronic acid dermal fillers: a comparison of rheological properties | 20.0 | 0 | 1 |
| Beyond Ebola: worldly viruses close to home. In an era of easy travel, exotic illnesses can end up on your doorstep | 20.0 | 0 | 1 |
| Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin a injection alone: a split‐face, rater‐blinded, randomized control trial | 20.0 | 0 | 1 |
| Value for money. Increased activity may put bright future at risk | 20.0 | 0 | 1 |
| Analysis of a Resident Aesthetic Clinic: Process for Rhinoplasty, Resident Experience, and Patient Satisfaction | 20.0 | 0 | 1 |
| Does private care provide value for money? 1. Why people prefer to pay for treatment | 20.0 | 0 | 1 |
| Does private care provide value for money? 2. How much is it going to cost? | 20.0 | 0 | 1 |
| Does private care provide value for money? 3. Why small is beautiful | 20.0 | 0 | 1 |
| Does private care provide value for money? 4. Where morale is high and recruitment no problem | 20.0 | 0 | 1 |
| Chemical Peels: Trichloroacetic Acid and Phenol | 20.0 | 0 | 1 |
| The Jessner’s-Trichloroacetic Acid Peel: An Enhanced Medium-Depth Chemical Peel | 20.0 | 0 | 1 |
| Discharge reductions--value for money? | 20.0 | 0 | 1 |
| Combination of In-Office Chemical Peels With a Topical Comprehensive Pigmentation Control Product in Skin of Color Subjects With Facial Hyperpigmentation | 20.0 | 0 | 1 |
| Move to another city: convenient location a 'must' | 20.0 | 0 | 1 |
| Exploring policy and financing options for long-term care in Taiwan | 20.0 | 0 | 1 |
| Combined antiviral treatment in HIV infection. Is it value for money? | 20.0 | 0 | 1 |
| PERIODIC PAYMENT PLANS FOR THE PURCHASE OF HOSPITAL CARE (GROUP HOSPITALIZATION) | 20.0 | 0 | 1 |
| A primer of facial chemical peel. | 20.0 | 0 | 1 |
| Dermal filler materials. | 20.0 | 0 | 1 |
| Clinical practice guidelines--do they enhance value for money in health care? | 20.0 | 0 | 1 |
| ANALYSIS OF PRIMARY TREATMENT AND PROGNOSIS OF SPONTANEOUS URTICARIA IN A LOCAL CLINIC OF OFFICE DERMATOLOGY | 20.0 | 0 | 1 |
| Alternative payment plans. | 20.0 | 0 | 1 |
| Assessing value for money in medical screening | 20.0 | 0 | 1 |
| Value for money in South African health care: findings of a review of health expenditure and finance | 20.0 | 0 | 1 |
| The potential impact of private long-term care financing options on Medicaid: the next thirty years | 20.0 | 0 | 1 |
| Chemical peel as a treatment for skin damage from excessive sun exposure | 20.0 | 0 | 1 |
| Dermal filler complications: a clinicopathologic study with a spectrum of histologic reaction patterns | 20.0 | 0 | 1 |
| Know your financing options | 20.0 | 0 | 1 |
| Dermatology procedures: microdermabrasion and chemical peels | 20.0 | 0 | 1 |
| The etiology of prolonged erythema after chemical peel | 20.0 | 0 | 1 |
| Orthopaedic healthcare worldwide: the transparent pricing revolution in healthcare | 20.0 | 0 | 1 |
| Emergency nurse. Value for money reports. A & E departments: value for money? | 20.0 | 0 | 1 |
| Chemical peels in plastic surgery | 20.0 | 0 | 1 |
| An unusual complication of Botox treatment for sialorrhoea | 20.0 | 0 | 1 |
| Clinical performance of a dermal filler containing natural glycolic Acid and a polylactic Acid polymer: results of a clinical trial in human immunodeficiency virus subjects with facial lipoatrophy | 20.0 | 0 | 1 |
| Foreign Body Granulomas after the Use of Dermal Fillers: Pathophysiology, Clinical Appearance, Histologic Features, and Treatment | 20.0 | 0 | 1 |
| Complications of medium depth and deep chemical peels | 20.0 | 0 | 1 |
| The Jessner's + TCA peel: a medium-depth chemical peel | 20.0 | 0 | 1 |
| Minimizing bruising following fillers and other cosmetic injectables | 20.0 | 0 | 1 |
| Impact of minimum price per unit of alcohol on patients with liver disease in the UK | 20.0 | 0 | 1 |
| Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler | 20.0 | 0 | 1 |
| Effects of tretinoin pretreatment on TCA chemical peel in guinea pig skin | 20.0 | 0 | 1 |
| Volume correction in the aging hand: role of dermal fillers | 20.0 | 0 | 1 |
| Medicines funding: Value for money is nothing new. | 20.0 | 0 | 1 |
| End of contract for Drug and Therapeutics Bulletin: bulletin is value for money | 20.0 | 0 | 1 |
| Ultrastructural Study of the Skin after Facial Chemical Peels and the Effect of Moisturization on Wound Healing | 20.0 | 0 | 1 |
| An unusual soft tissue radiopacity--radiographic appearance of a dermal filler | 20.0 | 0 | 1 |
| The role of dermabrasion and chemical peels in the treatment of patients with xeroderma pigmentosum | 20.0 | 0 | 1 |
| Trichloroacetic Acid Chemexfoliation (Chemical Peel) for Extensive Premalignant Actinic Damage of the Face and Scalp | 20.0 | 0 | 1 |
| Two Wrongs Do Not Make a Right: Flaws in Alternatives to Fee-for-Service Payment Plans Do Not Mean Fee-for-Service Is a Good Solution to Rising Prices Comment on "Fee-for-Service Payment - An Evil Practice That Must Be Stamped Out?" | 20.0 | 0 | 1 |
| Package pricing project improves hospital-physician relations. Interview by Donald E.L. Johnson. | 20.0 | 0 | 1 |
| Lip augmentation and contour correction with a ribose cross-linked collagen dermal filler | 20.0 | 0 | 1 |
| Facial fat grafting with a prototype injection control device | 20.0 | 0 | 1 |
| Too close to home? Experiences of Kurdish refugee interpreters working in UK mental health services | 20.0 | 0 | 1 |
| BRICS seek value for money as health-care costs rise | 20.0 | 0 | 1 |
| Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib? | 20.0 | 0 | 1 |
| Counseling Close to Home: Genetic Counselors' Experiences with their own Family Members | 20.0 | 0 | 1 |
| Close to Home | 20.0 | 0 | 1 |
| Value for money in attending conferences: Need to look more closely | 20.0 | 0 | 1 |
| Dermal fillers in patients on anticoagulants | 20.0 | 0 | 1 |
| Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma | 20.0 | 0 | 1 |
| The Royal College of Paediatrics and Child Health flagship meeting: is it value for money? | 20.0 | 0 | 1 |
| The real cost of care: focus on value for money, rather than price-tags | 20.0 | 0 | 1 |
| Effect of cross-linking reagents for hyaluronic acid hydrogel dermal fillers on tissue augmentation and regeneration | 20.0 | 0 | 1 |
| Hematuria following Botox treatment for upper limb spasticity: a case report. | 20.0 | 0 | 1 |
| Combination Jessner's solution and trichloroacetic acid chemical peel: technique and outcomes | 20.0 | 0 | 1 |
| Radiological impact of the use of calcium hydroxylapatite dermal fillers | 20.0 | 0 | 1 |
| Family physicians and the future of fee-for-service payment plans | 20.0 | 0 | 1 |
| Utlizing dermal fillers can literally change the face of HIV/AIDS. | 20.0 | 0 | 1 |
| Does the triple P-Positive Parenting Program provide value for money? | 20.0 | 0 | 1 |
| Value for money in health and welfare: a local study of the Home Help Service | 20.0 | 0 | 1 |
| Reconsidering value for money in periodontal treatment. | 20.0 | 0 | 1 |
| New president promises she is value for money | 20.0 | 0 | 1 |
| A novel, multistep, combination facial rejuvenation procedure for treatment of the whole face with incobotulinumtoxinA, and two dermal fillers- calcium hydroxylapatite and a monophasic, polydensified hyaluronic acid filler | 20.0 | 0 | 1 |
| Orthomorphic facial treatment of patients with sequelae of bilateral lip-palate cleft by the "mask-lifting" procedure | 20.0 | 0 | 1 |
| Value for money: Fit to negotiate. | 20.0 | 0 | 1 |
| Is public meningococcal C vaccination the preferred value for money at cost-neutral? | 20.0 | 0 | 1 |
| Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis | 20.0 | 0 | 1 |
| A Prospective, Split-Face, Randomized, Comparative Study of Safety and 12-Month Longevity of Three Formulations of Hyaluronic Acid Dermal Filler for Treatment of Nasolabial Folds | 20.0 | 0 | 1 |
| Medium-depth chemical peels in the treatment of acne scars in dark-skinned individuals | 20.0 | 0 | 1 |
| Safety and Efficacy of a Continuous-Flow, Injection-Assisted Device in Delivery of Dermal Fillers | 20.0 | 0 | 1 |
| Undesirable effects after treatment with dermal fillers | 20.0 | 0 | 1 |
| Fine needle aspiration cytology in the diagnosis of perioral adverse reactions to cosmetic dermal fillers. | 20.0 | 0 | 1 |
| "Small places close to home": toward a health and human rights strategy for the US. | 20.0 | 0 | 1 |
| Quality care close to home. Quality really counts when caring for patients in underserved areas | 20.0 | 0 | 1 |
| One-stop laser clinics: patients' preferences for treatment. | 20.0 | 0 | 1 |
| Long-term complications associated with permanent dermal fillers | 20.0 | 0 | 1 |
| Investing in health: is social housing value for money? A cost-utility analysis | 20.0 | 0 | 1 |
| A hundred year old price list | 20.0 | 0 | 1 |
| Financing options for turnarounds and bankruptcies. | 20.0 | 0 | 1 |
| Use of high-frequency ultrasound in the assessment of injectable dermal fillers | 20.0 | 0 | 1 |
| Use of Dermal Filler to Improve Exposure Keratopathy in a Patient with Restrictive Dermopathy | 20.0 | 0 | 1 |
| Chemical peels in aesthetic dermatology | 20.0 | 0 | 1 |
| Does animal health surveillance give value for money? | 20.0 | 0 | 1 |
| Chemical peels in richly pigmented patients | 20.0 | 0 | 1 |
| A five-patient prospective pilot study of a polycaprolactone based dermal filler for hand rejuvenation | 20.0 | 0 | 1 |
| Herpes reactivation after injection of dermal fillers | 20.0 | 0 | 1 |
| Community care: value for money nursing | 20.0 | 0 | 1 |
| Value for money in disease management of benign prostatic hyperplasia. | 20.0 | 0 | 1 |
| Refinements in combined chemical peel and simultaneous abrasion of the face | 20.0 | 0 | 1 |
| Public free anonymous HIV testing centers: cost analysis and financing options | 20.0 | 0 | 1 |
| Discussion: Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes | 20.0 | 0 | 1 |
| Rheological properties of cross-linked hyaluronic acid dermal fillers | 20.0 | 0 | 1 |
| Boi keeps Hedgehog close to home. | 20.0 | 0 | 1 |
| Safety and efficacy of hyaluronic acid for the correction of nasolabial folds: A meta-analysis | 20.0 | 0 | 1 |
| Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs | 20.0 | 0 | 1 |
| Comment on Grippaudo et al.: Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications. | 20.0 | 0 | 1 |
| EKG changes in relationship to the chemical peel | 20.0 | 0 | 1 |
| Phagocytosis of different particulate dermal filler substances by human macrophages and skin cells | 20.0 | 0 | 1 |
| Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers | 20.0 | 0 | 1 |
| Value for Money in Medicine | 20.0 | 0 | 1 |
| Microdermabrasion with chemical peel | 20.0 | 0 | 1 |
| Facial Volume Restoration with Permanent Dermal Filler (Artecoll-4) in Chinese Women | 20.0 | 0 | 1 |
| Is there any evidence for biofilms in dermal fillers? | 20.0 | 0 | 1 |
| Success in recruitment to randomized clinic trials: keep it simple and close to home … or is there more to it? | 20.0 | 0 | 1 |
| When it hits close to home. | 20.0 | 0 | 1 |